The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design
Open accessAbstract
Abstract As small molecule drugs become harder to develop and less cost effective for patient use, efficient strategies for their property improvement become increasingly important to global health initiatives. Improvements in the physical properties of Active Pharmaceutical Ingredients (APIs), without changes in the covalent chemistry, have long been possible through the application of binary component solids. This was first achieved through the use of pharmaceutical salts, within the last 10–15 years with cocrystals and more recently coamorphous systems have also been consciously applied to this problem. In order to rationally discover the best multicomponent phase for drug development, intermolecular interactions need to be considered at all stages of the process. This review highlights the current thinking in this area and the state of the art in: pharmaceutical multicomponent phase design, the intermolecular interactions in these phases, the implications of these interactions on the material properties and the pharmacokinetics in a patient. Graphical abstract Figure. No Caption available.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cambridge Structural Database: a quarter of a million crystal structures and rising
Allen, F. H. (2002) · Acta Crystallographica Section B Structural Science · doi:10.1107/s0108768102003890 · Cited by 9,898
Structural Inorganic Chemistry
(1971) · Nature · doi:10.1038/229453c0 · Cited by 5,766
Modeling and comparison of dissolution profiles
Costa, P., & Sousa Lobo, J. M. (2001) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(01)00095-1 · Cited by 5,509
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Supramolecular Synthons in Crystal Engineering—A New Organic Synthesis
Desiraju, G. R. (1995) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199523111 · Cited by 4,856
Encoding and decoding hydrogen-bond patterns of organic compounds
Etter, M. C. (1990) · Accounts of Chemical Research · doi:10.1021/ar00172a005 · Cited by 4,591
Cavallo, G., Metrangolo, P., Milani, R., Pilati, T., Priimagi, A., Resnati, G., & Terraneo, G. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00484 · Cited by 4,035
Ma, J. C., & Dougherty, D. A. (1997) · Chemical Reviews · doi:10.1021/cr9603744 · Cited by 3,477
Gordon, M., & Taylor, J. S. (1952) · Journal of Applied Chemistry · doi:10.1002/jctb.5010020901 · Cited by 2,621
Improving drug solubility for oral delivery using solid dispersions
Leuner, C. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00076-x · Cited by 2,574
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs
Vasconcelos, T., Sarmento, B., & Costa, P. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2007.09.005 · Cited by 1,566
Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates
Blagden, N., de Matas, M., Gavan, P. T., & York, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.011 · Cited by 1,448
Salt formation to improve drug solubility
Serajuddin, A. T. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.010 · Cited by 1,425
What is the True Solubility Advantage for Amorphous Pharmaceuticals?
Hancock, B. C., & Parks, M. (2000) · Pharmaceutical Research · doi:10.1023/a:1007516718048 · Cited by 1,358
Schottel, B. L., Chifotides, H. T., & Dunbar, K. R. (2008) · Chem. Soc. Rev. · doi:10.1039/b614208g · Cited by 1,133
Organic chemical crystallography
Kitaǐgorodskiǐ, A. I. (1961) · Consultants Bureau eBooks · Cited by 1,127
Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
Babu, N. J., & Nangia, A. (2011) · Crystal Growth & Design · doi:10.1021/cg200492w · Cited by 1,004
Vishweshwar, P., McMahon, J. A., Bis, J. A., & Zaworotko, M. J. (2006) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20578 · Cited by 968
Pharmaceutical cocrystals: along the path to improved medicines
Duggirala, N. K., Perry, M. L., Almarsson, Ö., & Zaworotko, M. J. (2016) · Chemical Communications · doi:10.1039/c5cc08216a · Cited by 928
Solubility Advantage of Pharmaceutical Cocrystals
Good, D. J., & Rodríguez-Hornedo, N. (2009) · Crystal Growth & Design · doi:10.1021/cg801039j · Cited by 841
Building co-crystals with molecular sense and supramolecular sensibility
Aakeröy, C. B., & Salmon, D. J. (2005) · CrystEngComm · doi:10.1039/b505883j · Cited by 770
Hancock, B. C., & Zografi, G. (1994) · Pharmaceutical Research · doi:10.1023/a:1018941810744 · Cited by 714
Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API
McNamara, D. P., Childs, S. L., Giordano, J., Iarriccio, A., Cassidy, J., Shet, M. S., Mannion, R., O'Donnell, E., & Park, A. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9032-3 · Cited by 690
Pharmaceutical cocrystals: An overview
Qiao, N., Li, M., Schlindwein, W., Malek, N., Davies, A., & Trappitt, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.037 · Cited by 665
Pharmaceutical cocrystals and poorly soluble drugs
Thakuria, R., Delori, A., Jones, W., Lipert, M. P., Roy, L., & Rodríguez-Hornedo, N. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.10.043 · Cited by 614
Report on the sixth blind test of organic crystal structure prediction methods
Reilly, A. M., Cooper, R. I., Adjiman, C. S., Bhattacharya, S., Boese, A. D., Brandenburg, J. G., Bygrave, P. J., Bylsma, R., Campbell, J. E., Car, R., et al. (2016) · Acta Crystallographica Section B Structural Science, Crystal Engineering and Materials · doi:10.1107/s2052520616007447 · Cited by 584
Handbook of Pharmaceutical Salts: Properties, Selection, and Use
(2002) · Chemistry International -- Newsmagazine for IUPAC · doi:10.1515/ci.2002.24.3.20a · Cited by 532
Simulation and prediction of in vivo drug metabolism in human populations from in vitro data
Rostami-Hodjegan, A., & Tucker, G. T. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2173 · Cited by 530
Trends in Solubility of Polymorphs
Pudipeddi, M., & Serajuddin, A. T. M. (2005) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20302 · Cited by 505
Khankari, R. K., & Grant, D. J. W. (1995) · Thermochimica Acta · doi:10.1016/0040-6031(94)01952-d · Cited by 485
Berge, S. M., Bighley, L. D., & Monkhouse, D. C. (1977) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600660104 · Cited by 479
Emerging trends in the stabilization of amorphous drugs
Laitinen, R., Löbmann, K., Strachan, C. J., Grohganz, H., & Rades, T. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.04.066 · Cited by 470
Cocrystals of Quercetin with Improved Solubility and Oral Bioavailability
Smith, A. J., Kavuru, P., Wojtas, L., Zaworotko, M. J., & Shytle, R. D. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200209j · Cited by 390
Guzmán, H. R., Tawa, M., Zhang, Z., Ratanabanangkoon, P., Shaw, P., Gardner, C. R., Chen, H., Moreau, J., Almarsson, Ö., & Remenar, J. F. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20906 · Cited by 381
Ilevbare, G. A., & Taylor, L. S. (2013) · Crystal Growth & Design · doi:10.1021/cg301679h · Cited by 366
Cytochrome P450-mediated metabolism in the human gut wall
Thelen, K., & Dressman, J. B. (2009) · Journal of Pharmacy and Pharmacology · doi:10.1211/jpp.61.05.0002 · Cited by 338
PBPK models for the prediction of in vivo performance of oral dosage forms
Kostewicz, E. S., Aarons, L., Bergstrand, M., Bolger, M. B., Galetin, A., Hatley, O., Jamei, M., Lloyd, R., Pepin, X., Rostami-Hodjegan, A., et al. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.09.008 · Cited by 315
Solubility of sparingly-soluble ionizable drugs
Avdeef, A. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.05.008 · Cited by 299
Eutectics as improved pharmaceutical materials: design, properties and characterization
Cherukuvada, S., & Nangia, A. (2014) · Chem. Commun. · doi:10.1039/c3cc47521b · Cited by 296
Physicochemical Properties of Pharmaceutical Co-Crystals: A Case Study of Ten AMG 517 Co-Crystals
Stanton, M. K., & Bak, A. (2008) · Crystal Growth & Design · doi:10.1021/cg800173d · Cited by 236
Cocrystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5
Kuminek, G., Cao, F., Bahia de Oliveira da Rocha, A., Gonçalves Cardoso, S., & Rodríguez-Hornedo, N. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.04.022 · Cited by 230
Bak, A., Gore, A., Yanez, E., Stanton, M., Tufekcic, S., Syed, R., Akrami, A., Rose, M., Surapaneni, S., Bostick, T., et al. (2008) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21280 · Cited by 218
Löbmann, K., Laitinen, R., Strachan, C., Rades, T., & Grohganz, H. (2013) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2013.03.026 · Cited by 195
Bioavailability of indomethacin-saccharin cocrystals
Jung, M.-S., Kim, J.-S., Kim, M.-S., Alhalaweh, A., Cho, W., Hwang, S.-J., & Velaga, S. P. (2010) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2010.01189.x · Cited by 171
Solubility prediction, solvate and cocrystal screening as tools for rational crystal engineering
Loschen, C., & Klamt, A. (2015) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12376 · Cited by 161
Physical Stability of Salts of Weak Bases in the Solid-State
Stephenson, G. A., Aburub, A., & Woods, T. A. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22405 · Cited by 161
Dean, P. M., Turanjanin, J., Yoshizawa‐Fujita, M., MacFarlane, D. R., & Scott, J. L. (2008) · Crystal Growth & Design · doi:10.1021/cg8009496 · Cited by 146
Baicalein–Nicotinamide Cocrystal with Enhanced Solubility, Dissolution, and Oral Bioavailability
Huang, Y., Zhang, B., Gao, Y., Zhang, J., & Shi, L. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24048 · Cited by 144
Ross, S. A., Lamprou, D. A., & Douroumis, D. (2016) · Chemical Communications · doi:10.1039/c6cc01289b · Cited by 141
Impact of pharmaceutical cocrystals: the effects on drug pharmacokinetics
Shan, N., Perry, M. L., Weyna, D. R., & Zaworotko, M. J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.942281 · Cited by 136
Jensen, K. T., Löbmann, K., Rades, T., & Grohganz, H. (2014) · Pharmaceutics · doi:10.3390/pharmaceutics6030416 · Cited by 136
Improving the Solubility and Bioavailability of Apixaban via Apixaban–Oxalic Acid Cocrystal
Chen, Y., Li, L., Yao, J., Ma, Y., Chen, J., & Lu, T. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b00266 · Cited by 131
Improving Solubility and Pharmacokinetics of Meloxicam via Multiple-Component Crystal Formation
Weyna, D. R., Cheney, M. L., Shan, N., Hanna, M., Zaworotko, M. J., Sava, V., Song, S., & Sanchez‐Ramos, J. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300169c · Cited by 128
Calixarene-cupped caesium: a coordination conundrums?
Harrowfield, J. M., Ogden, M. I., Richmond, W. R., & WHITE, A. H. (1991) · Journal of the Chemical Society Chemical Communications · doi:10.1039/c39910001159 · Cited by 126
Chan, H. C. S., Kendrick, J., Neumann, M. A., & Leusen, F. J. J. (2013) · CrystEngComm · doi:10.1039/c3ce40107c · Cited by 124
Cocrystals of the Tuberculosis Drug Isoniazid: Polymorphism, Isostructurality, and Stability
Swapna, B., Maddileti, D., & Nangia, A. K. (2014) · Crystal Growth & Design · doi:10.1021/cg501182t · Cited by 119
Role of Salt and Excipient Properties on Disproportionation in the Solid-State
Guerrieri, P., & Taylor, L. S. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9918-y · Cited by 106
The a to Z of Pharmaceutical Cocrystals: A Decade of Fast-Moving New Science and Patents
Almarsson, Ö., Peterson, M. L., & Zaworotko, M. J. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.29 · Cited by 101
How good are the crystallisation methods for co-crystals? A comparative study of piroxicam
Fucke, K., Myz, S. A., Шахтшнейдер, Т. П., Boldyreva, E. V., & Griesser, U. J. (2012) · New Journal of Chemistry · doi:10.1039/c2nj40093f · Cited by 94
Smith, A. J., Kavuru, P., Arora, K. K., Kesani, S., Tan, J., Zaworotko, M. J., & Shytle, R. D. (2013) · Molecular Pharmaceutics · doi:10.1021/mp4000794 · Cited by 81
X-ray and Neutron Diffraction in the Study of Organic Crystalline Hydrates
Fucke, K., & Steed, J. W. (2010) · Water · doi:10.3390/w2030333 · Cited by 56
Self-citationHerbstein, F. H., & Marsh, R. E. (1977) · Acta Crystallographica Section B · doi:10.1107/s0567740877008528 · Cited by 44
Lange, L., & Sadowski, G. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b00554 · Cited by 44
Characterization and Solubility Studies of Pharmaceutical Cocrystals of Eprosartan Mesylate
Bhandaru, J. S., Malothu, N., & Akkinepally, R. R. (2015) · Crystal Growth & Design · doi:10.1021/cg501532k · Cited by 43
Molecular mechanics of elastic and bendable caffeine co-crystals
Chen, C., Ghosh, S., Reddy, C. M., & Buehler, M. J. (2014) · Physical Chemistry Chemical Physics · doi:10.1039/c3cp55117b · Cited by 39
Cocrystal Solubilization in Biorelevant Media and its Prediction from Drug Solubilization
Lipert, M. P., Roy, L. P., Childs, S. L., & Rodríguez‐Hornedo, N. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24640 · Cited by 32
Ketkar, S., Pagire, S. K., Goud, N. R., Mahadik, K. R., Nangia, A. K., & Paradkar, A. R. (2016) · Crystal Growth & Design · doi:10.1021/acs.cgd.6b00759 · Cited by 31
Stanton, M. K., Kelly, R. C., Colletti, A. E., Langley, M., Munson, E. J., Peterson, M. L., Roberts, J., & Wells, M. C. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22502 · Cited by 29
Using Dissolution and Pharmacokinetics Studies of Crystal Form to Optimize the Original Iloperidone
Zhang, T., Yang, Y., Wang, H., Sun, F., Zhao, X., Jia, J., Liu, J., Guo, W. F., Cui, X., Gu, J., et al. (2013) · Crystal Growth & Design · doi:10.1021/cg4010104 · Cited by 24
Zhang, T., Yang, Y., Zhao, X., Jia, J., Su, H., He, H., Gu, J., & Zhu, G. (2014) · CrystEngComm · doi:10.1039/c4ce00784k · Cited by 17
Cited by
Creating Cocrystals: A Review of Pharmaceutical Cocrystal Preparation Routes and Applications
Karimi-Jafari, M., Padrela, L., Walker, G. M., & Croker, D. M. (2018) · Crystal Growth & Design · doi:10.1021/acs.cgd.8b00933 · Cited by 667
Boyd, B. J., Bergström, C. A. S., Vinarov, Z., Kuentz, M., Brouwers, J., Augustijns, P., Brandl, M., Bernkop-Schnürch, A., Shrestha, N., Préat, V., et al. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.104967 · Cited by 367
Machine learning directed drug formulation development
Bannigan, P., Aldeghi, M., Bao, Z., Häse, F., Aspuru-Guzik, A., & Allen, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.016 · Cited by 335
Pharmaceutical cocrystals: from serendipity to design to application
Kavanagh, O. N., Croker, D. M., Walker, G. M., & Zaworotko, M. J. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.023 · Cited by 323
Padrela, L., Rodrigues, M. A., Duarte, A., Dias, A. M. A., Braga, M. E. M., & de Sousa, H. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.010 · Cited by 262
Metadata
- Authors
- Berry, D. J., & Steed, J. W.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2017-08
- Volume
- 117
- Pages
- 3-24
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2603899979
- Cited by
- 406
- References
- 70
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.